Hopec Pharma is transforming the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) with HOPEC (UPEC-FimON), an innovative non-intravesical immunotherapy invented by Prof. Gilad Bachrach, Prof. Chamutal Gur, Prof. Ofer Mandelboim, and Dr. Vladimir Yutkin from the Hebrew University of Jerusalem and Hadassah Medical Center. This genetically modified Uropathogenic E. coli triggers a targeted immune response, offering higher efficacy, fewer side effects, and a scalable, cost-effective alternative to current treatment with Bacillus Calmette-Guérin (BCG). Founded in 2023 by Estee Rosen and Gadi Klarsfeld, Hopec Pharma leverages over 60 years of combined leadership in healthcare and pharma. The core team Dr. Ilan Winkler (VP Drug Development), Shoshi Friedman (VP Clinical Development), and Yohai Avrahami (Head of QA) brings extensive experience and execution strength within Israel’s biotech and clinical ecosystem. Hopec collaborates with leading Israeli partners: RS Ness serving as both CRO and regulatory affairs partner, Scinai Immunotherapeutics for GMP drug manufacturing, and BIFORUM for data management. In 2025, the company achieved major milestones: • Produced its first GMP clinical batch (DOR-100) • Received Helsinki approval (July 2025) for Phase 1/a+b • Signed clinical agreements with Hadassah and Sheba Medical Centers • Launched clinical trials (September 2025) • Awarded a grant from the Israel Innovation Authority (October 2025) Following strong preclinical results, Hopec entered human trials to validate HOPEC’s superior efficacy and safety. The company holds an exclusive IP license from Yissum and Hadasit with patents granted in the U.S., Europe, and China. With the NMIBC market projected to reach $8.6 billion by 2032, Hopec Pharma is well-positioned to lead the next generation of accessible, effective cancer immunotherapies that bring new hope and improve patients’ quality of life worldwide.